Pressure ulcer is the type of ulcer that occurs due to injury in which breakdown the skin and underlying tissues. The injury occurs due to application of a constant pressure for a certain period. This causes cessation of nutrition and oxygen supply to the tissues, tissue necrosis and tissue ischemia. It has been estimated that the tissues are capable of sustaining 30-32 mmHg pressure for a small period of time. Increased pressure causes microcirculatory occlusion which further leads to tissue death and ulceration. James J. Peters Veterans Affairs Medical Center is in the process of developing pioglitazone as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist for the treatment of pressure ulcers. Fundación Cardioinfantil Instituto de Cardiología is also in process of developing skin dressing for the treatment of pressure ulcer. Some of the universities having the pipeline of pressure ulcer include Fundación Cardioinfantil Instituto de Cardiología, James J. Peters Veterans Affairs Medical Center, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.